TCRXのROE（自己資本利益率）は？

Tscan Therapeutics IncのROEは-128.25%です。

TCRXの配当利回りは？

Tscan Therapeutics Incの配当利回りは0.00%です。

TCRXの品質スコア（Quality Score）は？

当社のAIはTCRXの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

TCRXは今が買い時ですか？

当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

TCRXはどのセクターに属しますか？

Tscan Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

TCRX (NASDAQ) 株価分析 | TSCAN THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

TCRX AI Analysis Summary

Our AI summary for TCRX: Tscan Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -128.25%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

TCRX

Tscan Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 93

USD 0.78

0.04 (5.91%) Day Change

Watchlist Portfolio Compare Chart

0.41

D/E

-128.3%

ROE

-61.5%

ROA

0.00%

Div Yield

TSCAN THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.78 Price 0.04 (5.91%) Day Change	NEWS SCORE: 93

TCRX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...

Deepscope 分析

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	93
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.78
PBV / Sector	0.50 / 44,105.10 GREAT
Earning Per Share	-2.01

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.61 M GREAT
Average 1W Daily Value	0.33 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1,360.61 / 97.23
NPM Average (%) / Sector	-1,611.64 / -1,697.84
NPM Change Average (%) / Sector	222.71 / 5,097.59 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-61.54 / 185,260.64
ROA Average (%) / Sector	-43.73 / 36,684.64
ROA Change Average (%) / Sector	19.24 / 422,221.42 GOOD
ROE (%) / Sector	-128.25 / 243,761.81
ROE Average (%) / Sector	-82.46 / 48,758.38
ROE Change Average (%) / Sector	24.79 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

登録情報

Analyze Date	2026-08-06 08:00:45
Symbol	TCRX
Name	TSCAN THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	61.07 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	48.13 / 9,702.21

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 830 Winter Street, Waltham, MA, United States, 02451

Phone: 857 399 9500

Website: https://www.tscan.com

Employees: 138

Sector: Healthcare >> Biotechnology

Description: TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.